Skip to main content
. 2020 Aug 12;45(10):783–791. doi: 10.1136/rapm-2019-101262

Figure 4.

Figure 4

Colocalization of CB2R on microglia and astrocytes in the spinal dorsal horn of BCP mice. (A, C) Representative blots and quantification of CB2R on postoperative days in the sham and tumor groups. n=3 for each time point per group. (B, D) representative blots and quantification of CB2R at 2, 6, 12, 24, 48 and 72 hours after the injection of JWH015 compared with vehicle injection respectively. n=3 for each time point per group. (E) Double immunostaining of CB2R (green) and OX42 (red) in the spinal dorsal horn performing in Con and tumor (day 14) group mice. (F) Double immunostaining of CB2R (green) and GFAP (red) in the spinal dorsal horn performing in Con and tumor (day 14) group mice. Arrows showed the representative merge of CB2R and OX42 or GFAP. (G) Immunofluorescence negative controls. immunostaining of goat anti-rabbit secondary antibody (green) and goat anti-mouse secondary antibody (red) in the ipsilateral spinal dorsal horn of the tumor (day 14) group of mice. Scale bar, 50 µm and 20 µm. All data are presented as the means±SD. BCP, bone cancer pain; CB2R, cannabinoid receptor 2; GFAP, a marker of astrocyte; OX42, a marker of microglia.